NEW DELHI: The AIIMS Ethics Committee on Saturday gave its nod for starting human clinical trial of the indigenously developed Covid-19 vaccine — Covaxin. The premier hospital is likely to begin the trials by enrolling healthy volunteers from Monday.
AIIMS-Delhi is among the 12 health facilities selected by Indian Council for Medical Research (ICMR) for conducting the first two phases of the human trials for Covaxin. “The AIIMS Ethics Committee gave its approval for starting human clinical trial of the indigenously developed Covaxin today.
Also read: FDA Haryana is monitoring sale, supply of medicines for COVID-19 treatment
Healthy volunteers having no comorbid conditions and without a history of Covid-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial,” Dr Sanjay Rai, professor at the centre for community medicine at AIIMS, said.
Anybody willing to participate in the trial can send an email to ctaiims.covid19@gmail.com or can call or test on 7428847499. The institute will also put up these contact details on its website. Covaxin has been developed by Hyderabad-based Bharat Biotech, along with ICMR and National Institute of Virology.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
